Phase I Clinical Trial of Oncolytic Delta-24-RGD (DNX-2401) with Biological Endpoints: Implications for Viro-Immunotherapy
American Association of Neurological Surgeons (AANS)Winner of the Journal on Neuro-Oncology Award, Frederick F. Lang Jr., MD, FAANS, recently presented his research into Delta-24-RGD at the 2015 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.